{"id":"tacrolimus-and-everolimus","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Neurotoxicity (tremor, headache)"},{"rate":null,"effect":"Dyslipidemia"}]},"_chembl":{"chemblId":"CHEMBL1908360","moleculeType":"Small molecule","molecularWeight":"958.24"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus binds to FK-binding protein and inhibits calcineurin, blocking T-cell receptor signaling and IL-2 production. Everolimus inhibits mTOR kinase, suppressing cell proliferation and immune response. Together, they provide synergistic immunosuppression to prevent organ rejection and graft-versus-host disease.","oneSentence":"Tacrolimus and everolimus are immunosuppressive agents that inhibit mTOR and calcineurin pathways to prevent T-cell activation and proliferation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:10:46.475Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in solid organ transplantation"},{"name":"Prevention and treatment of graft-versus-host disease (GVHD)"}]},"trialDetails":[{"nctId":"NCT06821542","phase":"PHASE3","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-04","conditions":"Chronic Graft-versus-host-disease","enrollment":9},{"nctId":"NCT07124078","phase":"PHASE2","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2026-03-31","conditions":"Chronic Graft-versus-host-disease","enrollment":60},{"nctId":"NCT06552169","phase":"PHASE2","title":"REgulatory T Cell Therapy to Achieve Immunosuppression REduction","status":"RECRUITING","sponsor":"Singulera Therapeutics Inc.","startDate":"2025-06-13","conditions":"Kidney Transplantation","enrollment":34},{"nctId":"NCT07083830","phase":"PHASE1","title":"ECP-DL Cell Infusion for Induction in Living Donor Kidney (LDK) Transplants","status":"NOT_YET_RECRUITING","sponsor":"Northwestern University","startDate":"2026-03-30","conditions":"Kidney Transplant Failure and Rejection, Kidney Transplant; Complications","enrollment":24},{"nctId":"NCT06832189","phase":"PHASE1","title":"EVR and EPO for Liver Transplant Tolerance","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-01-21","conditions":"Liver Transplant","enrollment":20},{"nctId":"NCT02081755","phase":"PHASE4","title":"Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Baylor Research Institute","startDate":"2014-03","conditions":"Carcinoma, Hepatocellular","enrollment":336},{"nctId":"NCT04542733","phase":"NA","title":"The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus and Leflunomide in Treatment of BK Virus Infection in Kidney Transplantation Recipient","status":"RECRUITING","sponsor":"King Chulalongkorn Memorial Hospital","startDate":"2021-02-10","conditions":"Kidney Transplant Infection, BK Virus Infection","enrollment":50},{"nctId":"NCT00799188","phase":"PHASE3","title":"CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2008-10","conditions":"Cardiac Transplantation, Skin Cancer","enrollment":175},{"nctId":"NCT04104438","phase":"PHASE4","title":"Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant","status":"COMPLETED","sponsor":"Fady M Kaldas, M.D., F.A.C.S.","startDate":"2021-01-15","conditions":"Asses Immunosuppression Modulation on Renal Recovery Post LT","enrollment":71},{"nctId":"NCT07173114","phase":"","title":"New Approaches for Evaluating the Interchangeability of Reference Materials and Quality Controls (COMET-MPL)","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2025-09-22","conditions":"Hospitalization, All Conditions","enrollment":300},{"nctId":"NCT00812786","phase":"PHASE4","title":"Pharmacokinetics of Immunosuppressive Drugs in Heart Transplant Patients","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2007-07","conditions":"Heart Transplant","enrollment":42},{"nctId":"NCT06280950","phase":"PHASE2","title":"Expanding Liver Transplant Immunosuppression Minimization Via Everolimus","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-09-12","conditions":"Liver Transplant","enrollment":340},{"nctId":"NCT02711826","phase":"PHASE1, PHASE2","title":"Treg Therapy in Subclinical Inflammation in Kidney Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-09-20","conditions":"Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant","enrollment":32},{"nctId":"NCT03577431","phase":"PHASE1, PHASE2","title":"Liver Transplantation With Tregs at MGH","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-03-29","conditions":"Liver Transplant","enrollment":9},{"nctId":"NCT03031470","phase":"PHASE2","title":"Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation","status":"TERMINATED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2015-03-10","conditions":"Ischemia-reperfusion Injury in Liver Transplant, Early Allograft Dysfunction","enrollment":40},{"nctId":"NCT03413722","phase":"","title":"Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2018-02-01","conditions":"End Stage Renal Disease","enrollment":30},{"nctId":"NCT06584773","phase":"PHASE4","title":"Efficacy of a Quadruple Immunosuppressor Regimen With mTOR Inhibitors in Sensitized Kidney Transplant Patients","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2015-06","conditions":"Disorder Related to Renal Transplantation","enrollment":80},{"nctId":"NCT03955172","phase":"NA","title":"Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2020-12-03","conditions":"Kidney Transplant Failure and Rejection","enrollment":20},{"nctId":"NCT03654040","phase":"PHASE1, PHASE2","title":"Liver Transplantation With Tregs at UCSF","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-22","conditions":"Liver Transplant","enrollment":42},{"nctId":"NCT06338306","phase":"","title":"Tacrolimus and Personalized Therapy to Prevent Acute Rejection Episodes","status":"RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2022-01-07","conditions":"Heart Transplant Failure","enrollment":25},{"nctId":"NCT04936971","phase":"PHASE4","title":"Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response","status":"WITHDRAWN","sponsor":"Edoardo Melilli","startDate":"2021-09","conditions":"Kidney Transplantation, Cytomegalovirus Infections","enrollment":""},{"nctId":"NCT03386539","phase":"PHASE3","title":"Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score","status":"UNKNOWN","sponsor":"Boston Children's Hospital","startDate":"2018-01-29","conditions":"Pediatric Heart Transplantation, Immunosuppression, Chronic Kidney Diseases","enrollment":211},{"nctId":"NCT04414735","phase":"NA","title":"Impact of Photopheresis in the Prevention of Acute Rejection in Highly Sensitized de Novo Kidney Transplant Recipients","status":"UNKNOWN","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":"Kidney Transplant Rejection","enrollment":30},{"nctId":"NCT03797196","phase":"PHASE4","title":"RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2019-07-29","conditions":"Renal Transplant Recipients, Elderly Patients, Immunosuppression","enrollment":374},{"nctId":"NCT03468478","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation","status":"COMPLETED","sponsor":"Hospital do Rim e Hipertensão","startDate":"2017-06-18","conditions":"Kidney Transplant Infection","enrollment":1209},{"nctId":"NCT02909335","phase":"PHASE3","title":"De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study","status":"WITHDRAWN","sponsor":"Rennes University Hospital","startDate":"2016-11","conditions":"Liver Transplantation","enrollment":""},{"nctId":"NCT05274308","phase":"","title":"Stability of Tacrolimus, Cyclosporine A, Everolimus and Sirolimus in Whole Blood Patient Samples","status":"COMPLETED","sponsor":"Thermo Fisher Scientific Oy","startDate":"2022-02-07","conditions":"Transplantation Drugs Stability","enrollment":46},{"nctId":"NCT02736227","phase":"NA","title":"Biomarkers Predicting Successful Tacrolimus Withdrawal and Everolimus (Zortress) Monotherapy Early After Liver Transplantation","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2016-03","conditions":"Liver Transplantation","enrollment":28},{"nctId":"NCT02088931","phase":"PHASE1","title":"Treg Adoptive Therapy for Subclinical Inflammation in Kidney Transplantation","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2014-03","conditions":"Late Complication From Kidney Transplant","enrollment":3},{"nctId":"NCT01935128","phase":"PHASE4","title":"Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction","status":"COMPLETED","sponsor":"University of Toledo Health Science Campus","startDate":"2013-07-03","conditions":"Renal Transplant","enrollment":55},{"nctId":"NCT02329808","phase":"","title":"Clinical Validation of a Dried Blood Spot Method for Analysis of Immunosuppressives and Antifungals in Pediatrics","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2015-06","conditions":"Hematologic Diseases, Oncology Problem, Kidney Diseases","enrollment":93},{"nctId":"NCT02137239","phase":"PHASE2","title":"Regimen Optimization Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-12-31","conditions":"Kidney Transplantation","enrollment":58},{"nctId":"NCT04867720","phase":"PHASE4","title":"Efficacy and Safety of CertiroBell® Tablet Plus Tacrolimus in Primary Living Donor Liver Transplant Recipients","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2021-03-16","conditions":"Liver Transplant","enrollment":112},{"nctId":"NCT01653847","phase":"NA","title":"Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2013-02","conditions":"End Stage Renal Failure With Renal Transplant","enrollment":88},{"nctId":"NCT02334488","phase":"PHASE3","title":"Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function","status":"COMPLETED","sponsor":"Poitiers University Hospital","startDate":"2014-12-11","conditions":"Chronic Kidney Disease","enrollment":329},{"nctId":"NCT01936519","phase":"NA","title":"Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2013-12-16","conditions":"Immunosuppression, Renal Failure","enrollment":24},{"nctId":"NCT03415750","phase":"PHASE4","title":"Everolimus and Tacrolimus Combination for Regression of Left Ventricular Hypertrophy in Renal Transplants","status":"COMPLETED","sponsor":"Edoardo Melilli","startDate":"2016-11","conditions":"Hypertrophy, Left Ventricular","enrollment":20},{"nctId":"NCT02188719","phase":"PHASE1","title":"Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-12-17","conditions":"Liver Transplantation","enrollment":15},{"nctId":"NCT02057965","phase":"PHASE2","title":"Mesenchymal Stromal Cell Therapy in Renal Recipients","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2014-03","conditions":"Renal Transplant Rejection, Fibrosis","enrollment":70},{"nctId":"NCT00377962","phase":"PHASE4","title":"Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-12","conditions":"Disorder Related to Cardiac Transplantation","enrollment":282},{"nctId":"NCT03256864","phase":"PHASE4","title":"Twice-daily Tacrolimus and Everolimus Convert to Once-daily Tacrolimus and Everolimus in Liver Transplant Recipient","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2016-01","conditions":"Liver Transplantation","enrollment":10},{"nctId":"NCT01239472","phase":"PHASE4","title":"Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant","status":"COMPLETED","sponsor":"Andre Barreto Pereira","startDate":"2011-01","conditions":"Renal Transplant Rejection, Immunosuppression","enrollment":30},{"nctId":"NCT02954198","phase":"NA","title":"Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2016-12-01","conditions":"Immunosuppression","enrollment":40},{"nctId":"NCT01807767","phase":"NA","title":"Myfortic in High MELD Liver Transplantation","status":"WITHDRAWN","sponsor":"Medical College of Wisconsin","startDate":"2013-03","conditions":"High Model for End-Stage Liver Disease (MELD) Score","enrollment":""},{"nctId":"NCT03932539","phase":"","title":"Improving Immunosuppressive Therapy in Heart Transplantation","status":"UNKNOWN","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2019-05-14","conditions":"Rejection Heart Transplant, Immunosuppression","enrollment":25},{"nctId":"NCT02077556","phase":"PHASE4","title":"Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2014-04","conditions":"Drug Interaction Potentiation","enrollment":14},{"nctId":"NCT02040584","phase":"PHASE3","title":"A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-12-20","conditions":"Liver Transplant","enrollment":217},{"nctId":"NCT01544491","phase":"PHASE3","title":"Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-08-17","conditions":"Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant","enrollment":106},{"nctId":"NCT01551212","phase":"PHASE4","title":"Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05-24","conditions":"Liver Transplantation","enrollment":339},{"nctId":"NCT01878786","phase":"PHASE2, PHASE3","title":"A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys","status":"TERMINATED","sponsor":"Matthew Cooper","startDate":"2013-06","conditions":"Delayed Graft Function","enrollment":25},{"nctId":"NCT01888432","phase":"PHASE3","title":"Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-09-25","conditions":"Liver Transplantation","enrollment":285},{"nctId":"NCT02970630","phase":"PHASE2","title":"Envarsus® Once Daily With Everolimus in Elderly Kidney Transplant Recipients: Pharmacokinetic and Clinical Study","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-01","conditions":"Kidney Transplantation","enrollment":28},{"nctId":"NCT02115113","phase":"PHASE3","title":"REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-03-28","conditions":"Liver Transplantation","enrollment":78},{"nctId":"NCT02084446","phase":"PHASE4","title":"Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant","status":"COMPLETED","sponsor":"Ronaldo de Matos Esmeraldo, MD","startDate":"2012-12","conditions":"Transplantation Infection, Cytomegalovirus Infections","enrollment":120},{"nctId":"NCT01950819","phase":"PHASE4","title":"Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-12-03","conditions":"End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis","enrollment":2037},{"nctId":"NCT01150097","phase":"PHASE3","title":"Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-03-31","conditions":"Liver Transplant Recipient","enrollment":284},{"nctId":"NCT01473732","phase":"NA","title":"Mechanisms and Treatment of Chronic Allograft Injury (CAI) Due to Calcineurin Inhibitor (CNI) Toxicity","status":"TERMINATED","sponsor":"Montefiore Medical Center","startDate":"2012-03","conditions":"Chronic Allograft Injury, Calcineurin Inhibitor Toxicity","enrollment":2},{"nctId":"NCT02096107","phase":"PHASE4","title":"Novartis Everolimus Transition","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2014-02","conditions":"Graft Dysfunction, Interstitial Fibrosis","enrollment":60},{"nctId":"NCT00862979","phase":"PHASE4","title":"A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-02-24","conditions":"Heart Transplantation","enrollment":162},{"nctId":"NCT03596970","phase":"PHASE3","title":"Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2015-09","conditions":"Liver Transplantation","enrollment":""},{"nctId":"NCT01707849","phase":"PHASE3","title":"The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation","status":"COMPLETED","sponsor":"Hospital Vall d'Hebron","startDate":"2012-10","conditions":"Hepatitis C Recurrence After Liver Transplant","enrollment":18},{"nctId":"NCT01911546","phase":"PHASE2","title":"Role of Everolimus in Highly Sensitized Patients","status":"COMPLETED","sponsor":"Joseph Kahwaji, MD, MPH","startDate":"2013-06","conditions":"Highly-sensitized Kidney Transplant Recipients","enrollment":20},{"nctId":"NCT01895049","phase":"PHASE4","title":"Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria","status":"COMPLETED","sponsor":"Helio Tedesco Silva Junior","startDate":"2013-08","conditions":"Kidney Transplantation, Cytomegalovirus","enrollment":171},{"nctId":"NCT01998789","phase":"PHASE2","title":"Everolimus Post Orthotopic Liver Transplant","status":"UNKNOWN","sponsor":"Tomoaki Kato","startDate":"2013-10","conditions":"Orthotopic Liver Transplant","enrollment":50},{"nctId":"NCT01612299","phase":"NA","title":"Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients","status":"WITHDRAWN","sponsor":"University of Kentucky","startDate":"2012-05","conditions":"Renal Transplant","enrollment":""},{"nctId":"NCT01276834","phase":"PHASE4","title":"Comparison of Immunosuppression on Progression of Arteriosclerosis in Renal Transplantation","status":"TERMINATED","sponsor":"Dianet Dialysis Centers","startDate":"2010-09","conditions":"Renal Transplantation","enrollment":13},{"nctId":"NCT01114529","phase":"PHASE3","title":"Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-08-09","conditions":"Kidney Transplantation","enrollment":828},{"nctId":"NCT01598987","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10","conditions":"Renal Function, Liver Transplant","enrollment":56},{"nctId":"NCT01843348","phase":"PHASE3","title":"12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12-27","conditions":"Kidney Transplantation, Renal Transplantation","enrollment":612},{"nctId":"NCT00160966","phase":"PHASE4","title":"Impact of Immunosuppressive Regimens on Polyomavirus-related Transplant Nephropathy","status":"COMPLETED","sponsor":"University of Giessen","startDate":"2004-09","conditions":"Polyomavirus Infections","enrollment":108},{"nctId":"NCT00369161","phase":"PHASE4","title":"A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-06","conditions":"Renal Transplantation","enrollment":228},{"nctId":"NCT01269684","phase":"PHASE4","title":"Immediate Conversion From Tacrolimus to Everolimus in Stable Maintenance Renal Transplant Recipients","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2008-08","conditions":"Kidney Transplantation","enrollment":""},{"nctId":"NCT01680861","phase":"PHASE3","title":"Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium","status":"COMPLETED","sponsor":"Gaetano Ciancio","startDate":"2012-11","conditions":"Transplant; Failure, Kidney","enrollment":32},{"nctId":"NCT01624948","phase":"PHASE4","title":"Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2012-09","conditions":"BK Virus Infection","enrollment":40},{"nctId":"NCT01625377","phase":"PHASE3","title":"A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12","conditions":"Liver Transplantation","enrollment":188},{"nctId":"NCT01169701","phase":"PHASE4","title":"24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-08","conditions":"Renal Transplant","enrollment":71},{"nctId":"NCT01631058","phase":"PHASE4","title":"Renal Transplantation in the Elderly - nEverOld Study","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2012-07","conditions":"Chronic Renal Failure (CRF), Graft Failure, Transplant; Failure, Kidney","enrollment":90},{"nctId":"NCT01025817","phase":"PHASE3","title":"Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-01","conditions":"Kidney Transplant","enrollment":613},{"nctId":"NCT01561404","phase":"PHASE4","title":"Effect of the Inhibition of the Mammalian Target of Rapamycin on Metabolism and Exercise","status":"TERMINATED","sponsor":"Josep M Cruzado","startDate":"2011-09","conditions":"Disorder Related to Renal Transplantation, Exercise, Aerobic, Muscle Strength","enrollment":3},{"nctId":"NCT01469884","phase":"PHASE4","title":"Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients","status":"COMPLETED","sponsor":"Irmandade Santa Casa de Misericórdia de Porto Alegre","startDate":"2011-11","conditions":"Renal Allograft, Hepatitis C","enrollment":30},{"nctId":"NCT01640743","phase":"NA","title":"Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation","status":"COMPLETED","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2010-03","conditions":"Kidney Transplantation","enrollment":58},{"nctId":"NCT01354301","phase":"PHASE4","title":"Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate","status":"COMPLETED","sponsor":"Hospital do Rim e Hipertensão","startDate":"2011-05","conditions":"Cytomegalovirus Infection, Renal Transplant Failure, Transplant; Complication, Rejection","enrollment":300},{"nctId":"NCT01134952","phase":"PHASE4","title":"Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"London Health Sciences Centre","startDate":"2010-06","conditions":"Hepatitis C","enrollment":11},{"nctId":"NCT02062892","phase":"PHASE4","title":"Differentiating Everolimus Versus Sirolimus in Combination With Calcineurin Inhibitors in Kidney Transplant Patients","status":"WITHDRAWN","sponsor":"University of Colorado, Denver","startDate":"2013-12","conditions":"Kidney Transplantation","enrollment":""},{"nctId":"NCT02036554","phase":"PHASE4","title":"Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft Recipients","status":"UNKNOWN","sponsor":"Seoul St. Mary's Hospital","startDate":"2013-03","conditions":"Kidney; Complications, Allograft","enrollment":234},{"nctId":"NCT00332839","phase":"PHASE4","title":"Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-11","conditions":"Renal Transplantation","enrollment":93},{"nctId":"NCT00965094","phase":"PHASE4","title":"Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-12","conditions":"Chronic Renal Failure","enrollment":36},{"nctId":"NCT01609673","phase":"NA","title":"Study of Everolimus in de Novo Renal Transplant Recipients","status":"TERMINATED","sponsor":"Helady Pinheiro, MD, PhD","startDate":"2013-03","conditions":"End Stage Renal Failure With Renal Transplant","enrollment":1},{"nctId":"NCT00622869","phase":"PHASE3","title":"Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-01","conditions":"Liver Transplantation","enrollment":719},{"nctId":"NCT01777204","phase":"","title":"Gastrointestinal Transit and Motility in Renal Transplant Recipients","status":"UNKNOWN","sponsor":"Universidade Estadual de Ciências da Saúde de Alagoas","startDate":"2011-01","conditions":"Change of Transit or Circulation, Effects of Immunosuppressant Therapy","enrollment":20},{"nctId":"NCT01312064","phase":"PHASE4","title":"De Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab Induction","status":"TERMINATED","sponsor":"National Taiwan University Hospital","startDate":"2011-04","conditions":"Renal Insufficiency","enrollment":2},{"nctId":"NCT01423708","phase":"PHASE2","title":"Everolimus in de Novo Liver Transplantation: a Multicentre Randomized Study","status":"UNKNOWN","sponsor":"Azienda Ospedaliera di Padova","startDate":"2010-02","conditions":"Liver Failure, Liver Diseases, Liver Cirrhosis","enrollment":117},{"nctId":"NCT01608412","phase":"PHASE4","title":"A Clinical Trial to Assess the Efficacy and Safety of the Conversion to Everolimus","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2012-02","conditions":"Kidney Transplant Recipients","enrollment":120},{"nctId":"NCT01446484","phase":"PHASE1, PHASE2","title":"Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection","status":"UNKNOWN","sponsor":"Pirogov Russian National Research Medical University","startDate":"2011-10","conditions":"End-Stage Renal Disease, Kidney Failure","enrollment":30},{"nctId":"NCT00170833","phase":"PHASE3","title":"Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2003-11","conditions":"Renal Transplantation","enrollment":80},{"nctId":"NCT01455649","phase":"PHASE4","title":"Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After Kidney Transplantation in Adults","status":"UNKNOWN","sponsor":"Deise de Boni Monteiro de Carvalho","startDate":"2011-11","conditions":"Kidney Transplant, Immunosuppression","enrollment":30},{"nctId":"NCT00223054","phase":"","title":"Polymorphism of the Cytochrome P450-system in Renal Transplants","status":"COMPLETED","sponsor":"University Hospital Schleswig-Holstein","startDate":"2005-03","conditions":"Function of Renal Transplant","enrollment":200},{"nctId":"NCT01399242","phase":"PHASE4","title":"Efficacy of Certican® in Combination With Myfortic® in Renal","status":"UNKNOWN","sponsor":"Hospital Universitário São José","startDate":"2011-08","conditions":"Disorder Related to Renal Transplantation","enrollment":40},{"nctId":"NCT01353053","phase":"","title":"Comparison of Two Immunosuppressive Regimens in Kidney Transplant Recipients With Deceased Donors With the Aim of Preventing the Development of Fibrosis / Atrophy of Reducing the Incidence of Cytomegalovirus Infection","status":"UNKNOWN","sponsor":"Federal University of São Paulo","startDate":"2010-07","conditions":"Disorder of Transplanted Kidney, Cytomegalovirus Infections","enrollment":82},{"nctId":"NCT00267189","phase":"PHASE3","title":"RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-11","conditions":"Liver Transplantation","enrollment":145}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prograf","Advagraf","Zortress","Certican"],"phase":"marketed","status":"active","brandName":"Tacrolimus and Everolimus","genericName":"Tacrolimus and Everolimus","companyName":"Chang Gung Memorial Hospital","companyId":"chang-gung-memorial-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tacrolimus and everolimus are immunosuppressive agents that inhibit mTOR and calcineurin pathways to prevent T-cell activation and proliferation. Used for Prevention of organ rejection in solid organ transplantation, Prevention and treatment of graft-versus-host disease (GVHD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}